Endocrinology, Diabetes and Metabolism; City of Health and Science University Hospital; Department of Medical Sciences; University of Turin, Turin, Italy.
Oncological Endocrinology; City of Health and Science University Hospital; Department of Medical Sciences; University of Turin, Turin, Italy.
Hypertens Res. 2024 Oct;47(10):2874-2883. doi: 10.1038/s41440-024-01807-3. Epub 2024 Aug 1.
The cardiometabolic implications of Non-Functioning Adrenal Incidentaloma (NFAI) is still matter of debate. This study takes a novel approach to analyze this association, accounting for the influence of various confounding factors. We present the findings of a retrospective, cross-sectional, and case-control study. Data from all NFAI patients in primary prevention, referred to the University of Turin between 2000 and 2023, were collected and compared with subjects without adrenal disease, using propensity score matching analysis. A total of 1997 patients were included (906 patients with NFAI; 1091 controls). Adrenal tumor group was associated with high levels of cardiovascular risk scores in both univariate and multiple linear regression analyses (Progetto CUORE: EC 11.00, 95% CI 2.72-44.46, p = 0.001; SCORE: EC 1.97, 95% CI 1.01-3.81, p = 0.046). Regarding cardiometabolic complications, multivariable logistic regression revealed an independent association between NFAI and ascending aorta dilation (OR 4.64, 95% CI 2.24-9.63, p = 0.000), after adjusting for age, sex, smoking status, metabolic syndrome, number of antihypertensive drugs, estimated glomerular filtration rate (eGFR), and normetanephrine levels. Propensity score matching analysis (1:1 matching ratio), based on the same logistic regression model, confirmed the association of NFAI with aortic dilation (β = 0.083, 95% CI 0.008-0.157, p = 0.030). No significant associations were found with metabolic syndrome, type II diabetes, eGFR <60 mL/min/1.73 m, microalbuminuria, atrial fibrillation, or hypertensive heart disease. This study suggests that patients with NFAI face increased cardiometabolic risk and high prevalence of ascending aorta dilation. Routine evaluation of NFAI patients should include thorough cardiovascular assessment and consideration of treatments aimed at reducing cardiovascular risk.
无功能性肾上腺 INCIDENTALOMA(NFAI)的心脏代谢影响仍然存在争议。本研究采用一种新方法来分析这种关联,考虑了各种混杂因素的影响。我们呈现了一项回顾性、横断面和病例对照研究的结果。收集了 2000 年至 2023 年期间在都灵大学接受原发性预防的所有 NFAI 患者的数据,并与无肾上腺疾病的患者进行比较,使用倾向评分匹配分析。共纳入 1997 例患者(906 例 NFAI 患者;1091 例对照)。在单变量和多变量线性回归分析中,肾上腺肿瘤组与心血管风险评分升高相关(Progetto CUORE:EC 11.00,95%CI 2.72-44.46,p=0.001;SCORE:EC 1.97,95%CI 1.01-3.81,p=0.046)。关于心脏代谢并发症,多变量逻辑回归显示,NFAI 与升主动脉扩张之间存在独立关联(OR 4.64,95%CI 2.24-9.63,p=0.000),调整年龄、性别、吸烟状况、代谢综合征、抗高血压药物数量、估计肾小球滤过率(eGFR)和去甲肾上腺素水平后。基于相同的逻辑回归模型,进行倾向评分匹配分析(1:1 匹配比例),证实了 NFAI 与主动脉扩张的相关性(β=0.083,95%CI 0.008-0.157,p=0.030)。与代谢综合征、2 型糖尿病、eGFR<60mL/min/1.73m、微量白蛋白尿、心房颤动或高血压性心脏病均无显著相关性。本研究表明,NFAI 患者面临增加的心脏代谢风险和升主动脉扩张的高发风险。对 NFAI 患者的常规评估应包括全面的心血管评估,并考虑采用降低心血管风险的治疗方法。